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were susceptible to cytolysis mediated by resting NK cells, 
and this susceptibility was significantly increased using IL-
15-activated NK cells. Flow cytometry and cytolytic assays 
were used to define the activating and inhibitory pathways 
of NK cells involved in recognizing and lysing RMS cells. 
NKG2D and DNAM-1 receptor-ligand interactions were 
essential in cytolysis by resting NK cells, as simultane-
ous blocking of both pathways resulted in almost complete 
abrogation of the cytotoxicity. In contrast, combined block-
ing of DNAM-1 and NKG2D only led to partial reduction 
of the lytic activity of IL-15-activated NK cells. In this 
respect, residual lysis was, at least partly, mediated by path-
ways involving the natural cytotoxicity receptors NKp30 
and NKp46. These findings support further exploration of 
NK cell-based immunotherapy as adjuvant modality in cur-
rent treatment strategies of RMS.
Keywords Rhabdomyosarcoma · Natural killer cells · 
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ARMS  Alveolar rhabdomyosarcoma
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KIRs  Killer immunoglobulin-like receptors
MIC  MHC class I chain-related
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Abstract Children with advanced stages (relapsed/refrac-
tory and stage IV) of rhabdomyosarcoma (RMS) have a 
poor prognosis despite intensive chemotherapy and autol-
ogous stem cell rescue, with 5-year survival rates ranging 
from 5 to 35 %. Development of new, additional treat-
ment modalities is necessary to improve the survival rate. 
In this preclinical study, we investigated the potential of 
resting and cytokine-activated natural killer (NK) cells to 
lyse RMS cell lines, as well as the pathways involved, to 
explore the eventual clinical application of (activated) NK 
cell immunotherapy. RMS cell lines (n = 3 derived from 
embryonal RMS and n = 2 derived from alveolar RMS) 
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NKG2D  Natural killer group 2 member D
PBMCs  Peripheral blood mononuclear cells
RMS  Rhabdomyosarcoma
ULBPs  UL16-binding proteins
Introduction
Childhood rhabdomyosarcoma (RMS), a soft tissue malig-
nant tumor of skeletal muscle origin, accounts for approxi-
mately 4 % of cancers among children aging 0–14 years 
with a peak incidence at 2–3 years [1]. Treatment and 
prognosis depend, in part, on the histology and molecular 
genetics of the RMS tumor. Patients diagnosed with alveo-
lar RMS (ARMS) have a significantly worse prognosis than 
those with embryonal RMS (ERMS). Patients with primary 
metastatic disease or relapse have a survival rate of <35 % 
[2, 3]. Despite the development of more intensive treatment 
protocols, the survival rate has hardly improved in the past 
20 years [1]. The poor prognosis in these patients makes it 
essential to pursue additional options for treatment, such as 
allogeneic hematopoietic stem cell transplantation (HSCT) 
and/or cell-mediated immunotherapy [4, 5].
The potential of immune cells to recognize and lyse tumor 
cells is currently explored to develop adjuvant immuno-
therapy against (pediatric) solid tumors. In this perspective, 
natural killer cells (NK cells) might be a promising tool. NK 
cells are bone marrow-derived lymphocytes defined by the 
expression of cell surface CD56 and the lack of CD3. NK 
cells do not bear clonally rearranged antigen-specific recep-
tors and secrete immune-modulating cytokines upon activa-
tion. In addition, they display potent cytolytic activity against 
a wide range of tumor cells and virus-infected cells [6].
Reactivity of NK cells toward target cells is regulated by 
the balance between inhibitory and activating signals deliv-
ered through interactions of NK cell receptors and their 
respective ligands on target cells. NK cell inhibitory signals 
are provided by HLA class I molecules, which either bind 
to inhibitory Killer immunoglobulin-like receptors (KIRs) 
or NKG2A/CD94 on NK cells [7, 8]. Activating signals are 
delivered by stress-induced ligands, expressed by the tumor 
itself, such as the MHC class I chain-related gene A and 
B (MIC A/B) and UL16-binding proteins (ULBP1-6). The 
natural killer group 2 member D (NKG2D) receptor on the 
NK cell binds to these ligands, resulting in an activating 
signal [9, 10]. Other activating NK cell receptors include 
DNAX accessory molecule-1 (DNAM-1), which can rec-
ognize the CD112 (Nectin-2) and CD155 (PVR) molecules 
[11]. A third family of activating receptors consists of the 
natural cytotoxicity receptors (NCRs) NKp30, NKp44 and 
NKp46, of which the ligands are largely unknown [12].
To date, a small number of in vitro studies suggest 
that cytokine-activated (natural) killer cells can recognize 
and lyse RMS cell lines [13–15]. However, the pathways 
involved in the NK cell-mediated cytolytic activity toward 
RMS cells are largely unidentified. The aim of this study 
was to define the pivotal molecular interactions involved in 




The RMS cell lines A204, TE671 (ERMS) and the RH30, 
RH41 (ARMS) were all obtained from DSMZ (Braunsch-
weig, Germany) and RD (ERMS) from ATCC (Manassa, 
VA, USA). Cells were maintained and cultured in DMEM 
Glutamax I high glucose (Life Technologies, Carlsbad, CA, 
USA), supplemented with 10 % heat-inactivated fetal calf 
serum (FCS, Greiner Bio-One, Kremsmuenster, Austria), 
1 % MEM-non-essential amino acids and penicillin/strep-
tomycin (100 U/mL and 100 μg/mL, respectively, both 
from Life Technologies). The NK-sensitive erythroleuke-
mia cell line K562 and the NK-resistant Burkitt lymphoma 
cell line Daudi (both ATCC) were cultured in RPMI Glu-
tamax I (Life Technologies) supplemented with 10 % heat-
inactivated FCS and penicillin/streptomycin (100 U/mL 
and 100 μg/mL, respectively). Cell lines were routinely 
screened for mycoplasma contamination by PCR.
Antibodies and flow cytometry
The following antibodies were used: CD16-FITC (clone 
#3G8), CD19-APC (#J4.119), CD56-RD1 (#N901), 
CD112-PE (R2.477.1), CD155 (#PV.404), Glycophorin 
A-PE (#KC16) and NKG2D-PE (#ON72) from Beckman-
Coulter (Fullerton, California, USA); CD3-PerCPCy5.5 
(#SK7), CD14/45 (lymphogate), CD33-PE (#P67.6), 
DNAM1-PE (#DX11), HLA-I-FITC (#G46-2.6) and 
MICA/B-PE (12D4) from BD Biosciences (San Jose, CA, 
USA); HLA-I (#W.6.32) from Biolegend (San Diego, CA, 
USA); MICA (#159227), ULBP-1 (#170818), ULBP-2 
(#165903), ULBP-3 (#166510) from R&D Systems (Min-
neapolis, MN, USA). As isotype controls mouse IgG1/2a 
(R&D Systems) or mouse IgG2b (DAKO, Glostrup, Den-
mark) were used. Unlabeled antibodies were detected with 
goat anti-mouse Ig-APC (BD Pharmingen, San Jose, CA, 
USA). To study natural cytotoxicity receptors (NCRs) 
ligand expression, Fc fusion proteins constructed by con-
necting part of the NCR molecule to the Fc part of a human 
IgG1 molecule were applied (NKp30, NKp44 and NKp46 
fusion proteins, 2.5 µg/mL; R&D Systems) and detected 
with goat antihuman Ig-A647 (Life Technologies). As iso-
type control, the anti-CD20 monoclonal antibody rituximab 
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(2.5 µg/mL, Roche, Woerden, the Netherlands) was used. 
To demonstrate the specificity of the fusion proteins, we did 
perform an experiment in which staining of IL-15-activated 
NK cells for NKp30, NKp44 and NKp46 using MoAbs 
was specifically inhibited with the relevant fusion protein 
(25 µg/mL). The reduction of staining was 81 % (MFI) and 
17 % (MFI) for NKp30-Fc and NKp46-Fc, respectively, 
and 94 % (% positive cells) for NKp44-Fc. Four-color flow 
cytometry was performed on a FACScalibur, and results 
were analyzed using Cellquest software (BD Biosciences).
Isolation and culture of NK cells
Peripheral blood mononuclear cells (PBMCs) were 
obtained from healthy blood-bank donors by Ficoll den-
sity gradient separation. NK cells were isolated using the 
MACS NK Cell Isolation Kit according to the manufac-
turer’s protocol (Miltenyi Biotech, Bergisch Gladbach, 
Germany). NK cell purity was 94–99 %. Freshly isolated, 
resting NK cells were cultured for 2–5 weeks in AIM-V 
supplemented with glutamax I (Life Technologies), 10 % 
pooled human serum (Sanquin, Rotterdam, the Nether-
lands), penicillin/streptomycin (100 U/mL and 100 μg/
mL, respectively) and 10 ng/mL recombinant human IL-15 
(Cellgenix, Freiburg, Germany).
Chromium release assays
Cytotoxicity was determined in a standard 4-h chromium 
release assay. Briefly, 1–3 × 106 target cells were incubated 
with 100 μL sodium-51-Chromate (51Cr, 3.7 MBq, Perki-
nElmer, Waltham, MA, USA) for 1 h. Effector cells, resting 
or IL-15-activated NK cells, were incubated for 4 h with 
2,500 target cells at eight effector:target (E:T) ratios. Maxi-
mum and spontaneous release was determined by incu-
bating targets in hydrochloric acid (2 N HCl) or medium, 
respectively. Supernatants were harvested and measured 
in a gamma counter (Perkin Elmer). Percentage of specific 
lysis was determined as: (experimental counts-spontaneous 
release)/(maximum release-spontaneous release) × 100. In 
blocking experiments, before the addition of target cells, 
NK cells were incubated for 20 min with blocking anti-
bodies specific for NKp30, NKp44 and NKp46 (all IgG1, 
clones #p30-15, #p44-8 and #9-E2, respectively, Bioleg-
end); for DNAM-1 (IgG1; #DX11; BD Pharmingen); for 
NKG2D (IgG1; #149810; R&D) or for HLA class I (IgG1; 
#DX17; BD Pharmingen) at a concentration of 10 μg/mL.
Co-cultivation
Freshly isolated NK cells were co-cultivated for 40 h 
with one of the RMS cell lines in the presence of IL-15 
(10 ng/mL). NK cells (1 × 106/well) were added to a 
semi-confluent layer of tumor cells, whereas controls con-
sisted of NK cells cultured in the absence of RMS cell lines 
in medium only or in medium with IL-15. NK cells were 
harvested after 40 h and analyzed for their phenotype and 
cytolytic potential.
Immunohistochemistry
Biopsies were taken at diagnosis from eight patients with 
ERMS. Four-μm sections containing representative tumor, 
as verified by an independent pathologist, were deparaffi-
nized, and citrate antigen retrieval and endogenous peroxi-
dases inactivation were performed. RMS cells in the biopsy 
sections were discerned by staining for myogenin (MYF4; 
#L026; Immunologic, Duiven, the Netherlands). Expres-
sion of the following ligands was assessed using rabbit pol-
yclonal antibodies overnight at 4 °C: CD155 (hpa012568), 
ULBP-1 (hpa007547) and CD112 (hpa012759; all Sigma-
Aldrich; Zwijndrecht, the Netherlands). MICA expression 
was assessed using a goat polyclonal antibody anti-MICA 
(AF1300, R&D Systems, Oxon, United Kingdom) over-
night at room temperature on sections pre-treated with 
10 % swine serum (Dako, Heverlee, Belgium) for 30 min at 
room temperature.
Antibody binding was detected by Liquid DAB + Sub-
strate Chromogen System (Dako, Heverlee, Belgium) 
after applying Dako Envision + System–HRP-labeled 
Polymer Anti-Rabbit for the rabbit polyclonals or Dako 
LSAB + System–HRP for the goat polyclonal-treated sec-
tions. Testis was used as an internal positive control for the 
activating NK ligands. All samples were counterstained 
with hematoxylin, mounted with Pertex, and examined 
under a light microscope using CellB acquisition software 
(Olympus, Zoeterwoude, the Netherlands).
Statistics
Statistical analyses were performed with GraphPad Prism 
version 6 using analysis of variance for comparing means 
between groups of samples or paired student t tests. Cor-
rection for multiple comparisons was applied using the 
Dunnett test correction. Error bars represent the standard 
error of the mean (SEM). A p value <0.05 was considered 
significant.
Results
RMS cell lines are highly susceptible to lysis 
by IL-15-activated NK cells
We have investigated the in vitro lytic activity of NK 
cells from healthy donors (effectors) against RMS cell 
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lines (targets) in a standard chromium release assay. NK 
cells were either used immediately after isolation (rest-
ing NK) or after activation with IL-15 for 2–5 weeks 
(IL-15-activated NK). Target cells were killed by rest-
ing NK cells (16 donors), although with a low efficacy 
as illustrated by the observation that high effector:target 
ratios (E:T > 40:1) were needed to obtain specific lysis 
above 25 % (Fig. 1a–c). Some variation in lytic activity 
of resting NK cells was observed among different donors 
(Fig. 1a, c).
In contrast, RMS susceptibility was strongly increased 
when using in vitro IL-15-activated NK cells (10 donors) 
as effectors. Il-15-activated NK cells efficiently recog-
nized and lysed all RMS cell lines investigated, even at 
effector:target ratios as low as 1:1 (Fig. 1a, b, d). Moreo-
ver, the variation between donors, as observed for resting 
NK cells, was less evident after activation of NK cells by 
IL-15.
Expression of NK cell receptor ligands on RMS cells
To explore the interaction pathways involved in the lysis 
of RMS cell lines by NK cells, expression patterns of 
activating and inhibitory ligands for NK cell receptors 
on RMS cell lines were investigated using flow cytom-
etry (FACS). Both ERMS and ARMS cell lines heteroge-
neously expressed HLA class I, the NKG2A/CD94 and 
potential KIR ligand, and ligands for the various activating 
NK receptors (Table 1; Fig. 3a). In general, both DNAM-1 
ligands (CD112 and CD155) were clearly expressed, 
whereas expression of NKG2D ligands, except for ULBP-
3, was low or even absent on the majority of the RMS cell 
lines (Table 1). None of the RMS cell lines detectably 
expressed NKp30, NKp44 or NKp46 ligands using the Fc 
fusion proteins.
To determine in vivo expression of the NKG2D and 
DNAM-1 ligands on RMS tumor cells, biopsy sections of 8 
Fig. 1  RMS cell lines are 
more susceptible to lysis by IL-
15-activated than by resting NK 
cells. Specific lysis of rhabdo-
myosarcoma (RMS) cell lines 
TE671 (a) and RH41 (b) by 
purified, resting NK cells (solid 
symbols) or IL-15-activated NK 
cells (open symbols), measured 
in triplicate (SEM shown by 
error bars) in a 4-h 51Cr release 
assay. Data of the percentage 
specific lysis of RMS cells 
by resting (solid bars) and 
IL-15-activated NK cells (open 
bars) at effector:target ratio 
40:1 (c resting NK cells: 16 
donors; activated NK cells: 7 
donors) and 1:1 (d resting NK 
cells: 16 donors; activated NK 
cells: 10 donors), respectively, 
are summarized. A p value 
<0.05 (indicated by *; <0.01 
indicated by **) using paired t 
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ERMS patients taken at diagnosis were stained for ULBP-1, 
MICA, CD112 and CD155 (Table 2; Fig. 2). Staining pat-
terns of the different ligands were correlated with the 
expression pattern of the RMS tumor marker MYF4. One 
tumor section expressed only one ligand (MICA); in the 
other seven biopsies, expression of at least a NKG2D and a 
DNAM-1 ligand was observed.
Lysis of RMS cell lines by resting NK cells is dependent 
on NKG2D and DNAM-1
To investigate the contribution of the NKG2D and DNAM-
1-mediated pathways to the interaction between NK cells 
and RMS cells, cytotoxicity assays were performed in the 
presence of blocking antibodies against the DNAM-1 and 
NKG2D receptor separately or in combination. In lysis 
assays performed with resting NK cells as effectors, block-
ing of DNAM-1 alone led to a more than 50 % reduction 
of the cytotoxicity toward all five cell lines, as depicted in 
Table 1  Phenotypical 
characterization of RMS cell 
lines
Expression of ligands for 
the inhibitory/activating NK 
cell receptors KIRs and the 
inhibitory receptor NKG2A/
CD94 (HLA class I) and 
for the activating NK cell 
receptors (NKG2D, DNAM-1 
and NCRs) was determined 
on RMS cell lines by flow 
cytometry. Mean fluorescence 
intensity (MFI) ratio of 
specific staining versus isotype 
control is depicted as:− = <2; 
± = 2–5; + = 5–10; 
++ = >10. ERMS embryonal 
rhabdomyosarcoma, ARMS 
alveolar rhabdomyosarcoma
A204 (ERMS) RD (ERMS) RH30 (ARMS) RH41 (ARMS) TE671 (ERMS)
KIR ligand
 HLA-I ++ + ++ − +
NKG2D ligands
 MICA/B ± ++ − − −
 MICA − + − − −
 ULBP1 − ± − ± ±
 ULBP2 − ± − ± +
 ULBP3 ± + ± + +
DNAM-1 ligands
 CD112 + ++ ± ++ ++
 CD155 + + + ++ ++
NCR ligands
 NKp30L − − − − −
 NKp44L − − − − −
 NKp46L − − − − −
Table 2  Expression of the NKG2D and DNAM-1 ligands on RMS 
tumor cells in biopsy sections
Expression of ligands for the activating NK cell receptors (NKG2D, 
DNAM-1) was determined on RMS biopsy sections of 8 ERMS 
patients by immunohistochemistry (−: no staining or weak mem-
brane staining in <10 % of the tumor cells; +: range of weak staining 
in at least 10 % of the tumor cells to intense membrane staining in 
≤30 % of the tumor cells; ++: intense membrane staining in >30 % 
of the tumor cells)
Patient # NKG2D ligands DNAM-1 ligands
MICA ULBP1 CD112 CD155
1 ++ + − +
2 + − + −
3 + + + −
4 + − − −
5 + − − ++
6 ++ − + −
7 − + − +
8 + − + −
Fig. 2  Immunohistochemistry of biopsy material for NKG2D and 
DNAM-1 ligands. Immunohistochemistry of NKG2D (MICA and 
ULBP1) and DNAM-1 (CD112 and CD155) ligands in biopsies of 8 
ERMS patients was performed. A representative example (patient #5; 
Table 2) is shown for the ligands, which illustrate the heterogeneous 
staining patterns with correlations to the staining pattern of the tumor 
marker myogenin (MYF4)
578 Cancer Immunol Immunother (2015) 64:573–583
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Fig. 3  Lysis of RMS cell lines 
by resting NK cells is dependent 
on NKG2D and DNAM-1-me-
diated pathways. a Histograms 
of expression levels (gray area 
isotype control thin line) of 
NKG2D (MIC A/AB, ULBP1-
3), DNAM-1 ligands (CD112 
and CD155) and HLA-1 for the 
cell line TE671 measured by 
flow cytometry. b Representa-
tive specific lysis of the cell line 
TE671 by resting (left panel) 
and IL-15-activated NK cells 
(right panel) in the presence 
or absence (open circle) of 
blocking antibodies to NKG2D 
(square), DNAM-1 (triangle) 
or the combination of these two 
receptors (closed circle). Error 
bars represent the SEM of 
triplicates. c Combined data for 
the lysis of the RMS cell lines 
by resting (5 donors, E:T ratio 
25:1, left panel) and IL-15-acti-
vated (6 donors, E:T ratio 10:1, 
right panel) NK cells in the 
presence of blocking antibodies 
to NKG2D (dark gray bars), 
DNAM-1 (light gray bars) 
and the combined antibodies 
(white bars). Data are depicted 
as percentage of the specific 
lysis obtained in the absence of 
blocking antibody. Error bars 
represent the SEM. Statistical 
analyses were performed using 
one-way ANOVA, followed by 
the Dunnett’s multiple com-
parisons test: p value <0.05 is 
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Fig. 3b for the cell line TE671 and in Fig. 3c (left panel) 
at the E:T ratio 25:1 for all five RMS cell lines. In con-
trast, blocking of NKG2D alone had far less impact, with 
the exception of the cell line RD (Fig. 3c). This might 
be explained by the clear expression of the NKG2D 
ligand MICA/B, next to ULBP-3, particularly on this cell 
line (Table 1). However, there was no evident correla-
tion between ligand expression and blocking pattern. The 
combination of DNAM-1 and NKG2D blocking led to an 
almost complete abrogation of killing by resting NK cells 
of all cell lines except for A204 (Fig. 3c, left panel).
Lysis by IL-15-activated NK cells not only depends 
on DNAM-1 and NKG2D
In contrast to resting NK cells, lysis of RMS cell lines by IL-
15-activated NK cells was only partially inhibited by com-
bined blocking of NKG2D and DNAM-1 blocking (Fig. 3b, 
c right panels). This observation suggests that more pathways 
are involved in the interaction between IL-15-activated NK 
cells and RMS cells. In this respect, flow cytometry analyses 
indicated that the intensity of expression of not only DNAM-1 
and NKG2D receptors but also of the NCRs, NKp30, NKp44 
and NKp46 was increased upon IL-15 activation of NK cells 
(supplemental Table 1). To investigate the functional impact 
of the enhanced expression of the NCRs, blocking antibodies 
specific for the NCRs were added in the cytotoxicity assays. 
Despite undetectable expression of each of the NCR ligands 
on the RMS cell lines by FACS analysis (Table 1), a signifi-
cant further reduction of cytolysis of three cell lines was seen 
when NKp46 was blocked on activated NK cells in combi-
nation with DNAM-1 and NKG2D blocking as compared to 
combined blocking of DNAM-1 and NKG2D alone (Fig. 4). 
Also, simultaneous blocking of NKp30 in combination 
with blocking of DNAM-1 and NKG2D led to a significant 
decrease of lysis in the cell lines TE671 and RD.
Fig. 4  Effect of blocking of 
NCRs on lysis of RMS cell 
lines by IL-15-activated NK 
cells. Combined data for the 
lysis of the RMS cell lines by 
IL-15-activated NK cells (5–7 
donors, E:T ratio 10:1) in the 
presence of blocking antibodies 
to NKp30, NKp44 and NKp46 
alone (solid bars) or together 
with the combined blocking 
antibodies to DNAM-1 and 
NKG2D (hatched bars). Data 
are depicted as percentage of 
the specific lysis obtained in the 
absence of a blocking antibody. 
Error bars represent SEM. 
Statistical analyses comparing 
combined blocking of DNAM-1 
and NKG2D in the presence 
of blocking of the indicated 
NCR with combined blocking 
of DNAM-1 and NKG2D alone 
were performed using one-way 
ANOVA, followed by the Dun-
nett’s multiple comparisons test: 
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Minor impact of HLA class I expression on NK 
cell-mediated cytolysis of RMS cell lines
Some HLA class I alleles are ligands of inhibitory and acti-
vating KIRs and the inhibitory NKG2A/CD94 receptor of 
NK cells. FACS analysis showed variable surface expres-
sion of HLA class I on the RMS cell lines, ranging from 
absent to strongly positive (Table 1).
To investigate whether this HLA class I expression 
has an impact on susceptibility to NK cell cytotoxicity, 
the HLA class I-mediated interaction was blocked in 
vitro by pre-incubating the tumor cells with a monoclo-
nal antibody directed to HLA class I (clone DX17) prior 
to the chromium release assay. After blocking of HLA 
class I, the sensitivity of RMS cell lines to cytolysis by 
resting NK cells remained unchanged (Fig. 5a) or only 
showed a trend to be increased (Fig. 5b). Moreover, no 
clear effect was seen in assays with IL-15-activated NK 
cells (data not shown). These results suggest that expres-
sion of HLA class I on RMS cells has no major impact 
on the interaction between allogeneic NK cells and RMS 
cell lines.
Cytotoxicity of NK cells is not affected after co-cultivation 
with RMS cell in vitro
It cannot be excluded that RMS cells induce reduction 
of NK cell-mediated lysis, either via cell–cell contact or 
by production of soluble factors, representing a potential 
mechanism of RMS cells to escape from NK cell-mediated 
lysis. Hence, we performed assays to investigate possi-
ble changes in NK cell receptor expression and potential 
alteration of the lytic capacity of activated NK cells after 
co-cultivation with RMS cell lines [16]. After 40 h of co-
cultivation with RMS cell lines, only a diminished expres-
sion of DNAM-1 receptor was observed on NK cells iso-
lated from 1 out of the 4 donors investigated, irrespective 
of the RMS cell line used (Supplemental Figurer 1A). Most 























































Fig. 5  Neither HLA class I blocking nor co-cultivation with RMS 
cells affect NK cell-mediated cytotoxicity. a Specific lysis by resting 
NK cells of the cell line TE671 at different effector:target (E:T) ratios 
in the absence (solid symbol) or presence (open symbol) of anti-HLA 
class I blocking antibody Dx17. b Combined data of 3 independent 
assays and donors for the lysis of the RMS cell lines by resting NK 
cells at an E:T ratio of 25:1. Data are depicted as percentage of the 
specific lysis obtained in the absence of the anti-HLA class I anti-
body Dx17. Error bars represent SEM. c Purified NK cells were co-
cultivated for 40 h with RMS cells in the presence of IL-15. Control 
cultures consisted of NK cells alone in the absence (closed circles) 
or presence of IL-15 (open circles). After culture, the NK cells were 
harvested and specific lysis of Daudi cells was measured at various 
effector:target (E:T) ratios
▸
important, none of the co-cultivation conditions resulted in 
a decrease in the lytic potential of IL-15-activated NK cells 
toward K562 (target sensitive to resting and activated NK 
cells; data not shown) or Daudi (target sensitive to activated 
NK cells only; Fig. 5c and Supplemental Figure 1B).
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Discussion
In line with previous reports from our group investigating 
the in vitro cytotoxicity of NK cells against Ewing sar-
coma and osteosarcoma [17, 18], we have demonstrated 
that cytokine-activated NK cells are much more effective 
in killing RMS target cells than resting NK cells. In gen-
eral, the crucial role of DNAM-1 and NKG2D receptor-
ligand interactions in NK cell-mediated killing of tumor 
cells is also observed in earlier reports on pediatric solid 
tumors and others tumors such as ovarian carcinoma, mela-
noma and acute myeloid leukemia [13, 17–23]. From these 
reports, the picture arises that the relative contribution of 
DNAM-1 and NKG2D receptor-ligand interactions varies 
between tumors and is different for resting and cytokine-
activated NK cells. Similar to freshly isolated ovarian car-
cinoma [21], the DNAM-1 pathway seems relatively more 
important for the recognition of RMS cells by resting NK 
cells than the NKG2D-mediated pathway, illustrated by the 
observation that blocking of the DNAM-1 receptor resulted 
in significantly decreased lysis. Nevertheless, despite 
mostly weak or even undetectable expression of NKG2D 
ligands on RMS cells, simultaneous blocking of DNAM-1 
and NKG2D led to almost complete abrogation of the cyto-
toxicity of resting NK cells. Of note, the overall intensity of 
expression of either DNAM-1 ligands or NKG2D ligands 
on the different RMS cell lines (Table 1) did not clearly 
correlate with the level of reduction of cytolysis by resting 
NK cells obtained after blocking with anti-DNAM-1 and 
anti-NKG2D, respectively (Fig. 3c).
The observation that blocking of both receptors on 
IL-15-activated NK cells only reduced cytotoxicity by 
25–50 % indicates that more receptor-ligand pathways 
are involved in the cytolysis of RMS cells in this setting. 
In view of the observation that the expression intensity of 
NCRs was found to be increased on NK cells after IL-15 
activation, and a role for NKp30 and NKp46 has been 
reported in killing of neuroblastoma cell lines [19], each 
of the NCRs, i.e., NKp30, NKp44 and NKp46, alone or in 
combination with DNAM-1 and NKG2D receptors, was 
blocked during the cytotoxicity assays. Remarkably, block-
ing of NKp30 or NKp46 receptors combined with block-
ing of DNAM-1 and NKG2D receptors resulted in an addi-
tional reduction of the lytic activity of IL-15-activated NK 
cells against 2 and 3 RMS cell lines, respectively, although 
expression of NCR ligands was not detected by FACS anal-
ysis. It remains speculative whether the expression inten-
sity of the NCR ligands is too low for detection by flow 
cytometry using fusion proteins, whereas expression was 
observed in other types of tumors such as neuroblastoma 
and osteosarcoma cell lines (data not shown).
Not only activating receptors are important for the regu-
lation and triggering of NK cells. Expression of HLA class 
I molecules is reported to mediate NK cell tolerance [12]. 
Despite heterogeneous expression levels of HLA class I, all 
RMS cell lines were sensitive to NK cell-mediated killing 
and no apparent correlation was observed between suscep-
tibility to NK lysis and the expression level of HLA class 
I molecules. Furthermore, blocking of HLA class I only 
showed a trend to increase the susceptibility to lysis by NK 
cells. This lack of a significant effect could be explained 
by the likelihood that the signal of activating ligands is too 
strong to be surpassed by inhibitory ligands or the level of 
class I expression was too low to give sufficient inhibitory 
signals [24].
There is evidence that tumors are capable of escaping 
immunosurveillance by down regulating T cell or NK 
cell function [25, 26]. Raffaghello et al. [26] reported 
an immune evasion strategy employed by neuroblastoma 
cells through the production of a soluble form of MICA, 
which resulted in decreased expression of NKG2D recep-
tors on CD8+ T cells of healthy controls and decreased 
cytotoxicity of activated NK cells. To investigate whether 
RMS cell lines are capable to inhibit NK cell function 
as an evasion strategy, RMS cells and NK cells were co-
cultivated in the presence of IL-15. The results showed 
that RMS cells, in contrast to some osteosarcoma and 
neuroblastoma cell lines, at least in this in vitro setting, 
do not negatively affect cytolytic NK cell function [16, 
27]. Neither the expression pattern of activating NK cell 
receptors nor the lytic capacity was altered after 40 h of 
co-cultivation. As we did not observed alteration in lytic 
capacity of NK cells after co-cultivation with RMS cells, 
the release of NKG2D ligands by RMS cell lines repre-
senting a possible immune escape mechanism was not 
investigated.
Since RMS cell lines are susceptible to (allogeneic) NK 
cell-mediated lysis, this tumor may be a suitable target 
for immunotherapy by adoptive transfer of (in vitro acti-
vated) NK cells. In haploidentical HSCT for children with 
hematologic malignancies and/or solid tumors, beneficial 
anti-tumor effects could be observed in the presence of an 
inhibitory KIR ligand mismatch between donor and recipi-
ent [28–31]. To further enhance this graft-versus-tumor 
effect, several studies were performed with transfer of in 
vitro activated NK cells. The strategies of adoptive NK 
cell therapy were found to be feasible and tolerable with-
out enhancing the risk of graft-versus-host disease or other 
adverse events, and anti-tumor efficacy has been reported 
in some studies [32–35].
Taken together, a new treatment strategy using addi-
tional NK cell-based immunotherapy could provide a novel 
therapeutic option for children with relapsed or stage IV 
RMS. The in vitro data presented in this report motivate to 
further investigate whether RMS might be susceptible to 
NK cell-mediated killing in vivo as well.
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